Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin.

Warren Pharmaceuticals, Ossining, NY 10562, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 09/2008; 105(31):10925-30. DOI: 10.1073/pnas.0805594105
Source: PubMed

ABSTRACT Erythropoietin (EPO), a member of the type 1 cytokine superfamily, plays a critical hormonal role regulating erythrocyte production as well as a paracrine/autocrine role in which locally produced EPO protects a wide variety of tissues from diverse injuries. Significantly, these functions are mediated by distinct receptors: hematopoiesis via the EPO receptor homodimer and tissue protection via a heterocomplex composed of the EPO receptor and CD131, the beta common receptor. In the present work, we have delimited tissue-protective domains within EPO to short peptide sequences. We demonstrate that helix B (amino acid residues 58-82) of EPO, which faces the aqueous medium when EPO is bound to the receptor homodimer, is both neuroprotective in vitro and tissue protective in vivo in a variety of models, including ischemic stroke, diabetes-induced retinal edema, and peripheral nerve trauma. Remarkably, an 11-aa peptide composed of adjacent amino acids forming the aqueous face of helix B is also tissue protective, as confirmed by its therapeutic benefit in models of ischemic stroke and renal ischemia-reperfusion. Further, this peptide simulating the aqueous surface of helix B also exhibits EPO's trophic effects by accelerating wound healing and augmenting cognitive function in rodents. As anticipated, neither helix B nor the 11-aa peptide is erythropoietic in vitro or in vivo. Thus, the tissue-protective activities of EPO are mimicked by small, nonerythropoietic peptides that simulate a portion of EPO's three-dimensional structure.

Download full-text


Available from: Tiziana Mennini, Jun 27, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: the hematopoietic activity of erythropoietin (EPO) is mediated by the classic EPO receptor (EpoR) homodimer, whereas the tissue-protective effects by a hetero-complex between EpoR and the β-common receptor (βcR). Here, we investigated the effects of a novel, selective ligand of the hetero-complex EpoR/βcR (pyroglutamate helix B surface peptide [pHBSP]) in mice chronically exposed to a diet enriched in sugars and saturated fats.
    British Journal of Pharmacology 08/2014; DOI:10.1111/bph.12888 · 4.99 Impact Factor
  • Source
    Acta Orthopaedica 02/2014; 85(S353):1-29. DOI:10.3109/17453674.2013.869716 · 2.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recombinant human erythropoietin (rhEPO), a glycohormone, is one of the leading biopharmaceutical products. The production of rhEPO is currently restricted to mammalian cell expression systems because of its highly complex glycosylation pattern, which is a major determinant for drug-efficacy. Here we evaluated the ability of plants to produce different glycoforms of rhEPO. cDNA constructs were delivered to Nicotiana benthamiana (N. benthamiana) and transiently expressed by a viral-based expression system. Expression levels up to 85 mg rhEPO/kg fresh leaf material were achieved. Moreover, co-expression of rhEPO with six mammalian genes required for in planta protein sialylation resulted in the synthesis of rhEPO decorated mainly with bisialylated N-glycans (NaNa), the most abundant glycoform of circulating hEPO in annemia patients. A newly established peptide tag (ELDKWA) fused to hEPO was particularly well suited for purification of the recombinant hormone based on immunoaffinity. Subsequent lectin chromatography allowed enrichment of exclusively sialylated rhEPO. All plant-derived glycoforms exhibited high biological activity as determined by a cell-based receptor binding assay. The generation of rhEPO carrying largely homogeneous glycosylation profiles (GnGnXF, GnGn and NaNa) will facilitate further investigation of functionalities which might have a direct impact for medical applications.
    Biotechnology Journal 03/2013; 8(3). DOI:10.1002/biot.201200363 · 3.71 Impact Factor